We are recruiting an ambitious scientist who will play a central role in the scientific implementation and management of an EU-funded contribution to the Human Cell Atlas, in a project that seeks to build an “organoid cell atlas” by massive-scale single-cell genomics and epigenome sequencing of human organoids for brain, colon, and several other human organs.
The position will be based in the laboratory of Christoph Bock at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna. It will involve close collaborations with many leading scientists in the organoids and single-cell sequencing fields.
Single-cell technologies provide a fundamentally new perspective for understanding biology, with profound potential to drive therapeutic advances. To foster swift progress in this important field, the Human Cell Atlas provides global coordination for the establishment and utilization of a single-cell reference atlas comprising all human cells / cell types. As a European contribution to the Human Cell Atlas, the EU has selected a project coordinated by CeMM that will establish an initial “Organoid Cell Atlas” with comprehensive single-cell sequencing and single-cell imaging of human organoids, large-scale computational analysis, and case studies on the biomedical relevance of this community resource (including CRISPR single-cell sequencing and high-content drug screening). The advertised position provides excellent opportunities for pursuing and publishing high-impact research, while also involving important project management tasks in the context of an international consortium.
The Lab (http://epigenomics.cemm.oeaw.ac.at/)
The Medical Epigenomics Lab at CeMM pursues interdisciplinary, highly collaborative research aimed at understanding disease biology and advancing precision medicine through wet-lab and computational methods. The lab is internationally well connected and active in several fields:
- Single-cell genomics/epigenomics. Many diseases show deregulation of epigenetic and transcription-regulatory cell states. As a member of the Human Cell Atlas, we use single-cell sequencing to dissect the molecular basis of cancer, immunity, and organoid biology.
- Machine learning in bioinformatics. Massive biomedical dataset pose new analytical challenges. As a fellow of the European Laboratory for Learning and Intelligent Systems (ELLIS), we develop methods for interpretable deep learning and AI in biomedicine.
- High-throughput technology. Many groundbreaking biomedical advances are driven by new technologies. Our lab thus invests heavily into technology development, including single-cell sequencing, CRISPR screens, epigenome editing, and synthetic biology.
- Personalized medicine. Emerging technologies enable a new paradigm of patient-centric medicine with deep biological understanding. We develop and validate assays and algorithms for translating the value of personalized medicine into routine clinical practice.
The Principal Investigator (https://scholar.google.com/citations?user=9qSsTcIAAAAJ)
Christoph Bock is a principal investigator at CeMM. His research group combines experimental biology (high-throughput sequencing, epigenetics, CRISPR screening, synthetic biology) with computer science (bioinformatics, machine learning, artificial intelligence). He is also a guest professor at the Medical University of Vienna and scientific coordinator of the Biomedical Sequencing Facility at CeMM. He is the coordinator of an upcoming EU Horizon 2020 project on the single-cell analysis of human organoids, which constitutes part of the European contribution to the Human Cell Atlas, and he co-founded Genom Austria, a citizen science project that is the Austrian partner in the International Network of Personal Genome Projects. He is a member of the Young Academy of the Austrian Academy of Sciences (since 2017) and recipient of several major research awards, including the Max Planck Society’s Otto Hahn Medal (2009), a New Frontier Group grant by the Austrian Academy of Sciences (2015-2020), an ERC Starting Grant (2016-2021), and the Overton Prize of the International Society of Computational Biology (2017). He co-founded Aelian Biotechnology, a Vienna-based startup company that develops single-cell methods for high-throughput drug discovery.